888-536-7697 ext. 6852
oncologysupply.com
☰
˟
LOGIN FAILED - Invalid User Name / Password. Please Try Again
You have been logged out. Thank you
This is a warning feedback message
Pricing Alert

Oncology Resources

 Access branded clinical information sponsored by Bristol-Myers Squibb.
Pricing Alert

INJECTAFER Savings Program

 Help your patients afford their IV iron treatment. Please see Important Safety Information, full Prescribing Information and Terms and Conditions.
Pricing Alert

Evidence Exchange Balance

 White paper from Xcenda and NPC highlights findings from payers and providers on evidence that is vital when deciding formularies and care pathways.
Pricing Alert

Become a Member

 Let Innovation Cancer focus on the health of your practice, so you can focus on the health of your patients.
Pricing Alert

Advancing I-O Research

 Ongoing Immuno-Oncology research at Bristol-Myers Squibb seeks to understand how to restore the body’s natural ability to fight cancer. Take a closer look.
Pricing Alert

Understanding QRUR

 Learn more about how to obtain and understand the Quality and Resource Use Report (QRUR) for your practice.
Pricing Alert

Protect Cancer Care

 In a recent article, Jeff Vacirca discusses the devastating impact of the most recent MedPAC recommendations on community practices.
Pricing Alert

Economic Modeling

 Access Protocol Analyzer through the Nucleus Connect platform to help your practice better manage its drug spend and optimize reimbursements.
Pricing Alert

AdvanceIQ Network

 Learn more about AdvanceIQ Network, a resource designed to better match our practices with clinical trials and research opportunities.
Pricing Alert

Access 2017 Guide

 The ACCC has released their new guide designed to help practices identify services for patients struggling with the financial burdens associated with cancer care.
Breaking News
Consider a 2-dose IV iron treatment course with a co-pay assistance program
New Contract Offering for FASLODEX (fulvestrant) Injection
Urothelial carcinoma option now approved for previously treated advanced disease
A new therapy NOW APPROVED in relapsed follicular lymphoma (FL)
Tailor their treatment with Rubraca® (rucaparib) tablets
View More
Videos
The Provider Perspective
Video 1 of 6
The Provider Perspective
AMERISOURCEBERGEN RESOURCES
Community Counts
Advocacy and legislative support
 Innovation Cancer
Technology, marketing, and consulting
 US Bioservices
Specialty pharmacy solutions
 OncologySupply
Chemo and supportive care orders